Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. The BPSI is one of the most direct snapshots of how people inside biopharma view the road ahead. Nearly 1,000 industry insiders took part in the BPSI last quarter. Your input helps keep the benchmark representative and relevant, and shapes the industry's thinking. Responses are anonymous, and participants will be first to receive a complimentary copy of the report. Tom Randall Head of Endpoints Signal